ABUS

4.0201.23%
RH

R. Hector Mackay-Dunn

Corporate Secretary

Mr. R. Hector MacKay-Dunn, J.D., Q.C, BA, LLB, K.C. has been Corporate Secretary of Digital Shelf Space Corp. since November 28, 2014. He served as Independent Director at Aurinia Pharmaceuticals Inc. since June 26, 2019 until September 2024. Mr. MacKay-Dunn serves as Primary Corporate Legal Advisor at Klean Industries Inc. He has been Corporate Secretary at Tekmira Pharmaceuticals Corp. since May 2010. He serves as a Senior Partner at the law firm of Farris, Vaughan, Wills & Murphy LLP. He is a Corporate Secretary of Arbutus Biopharma Corporation since May 2010. He joined the Arbutus Biopharma Corporation in May 2010. He was a Secretary of MOVIT Media Corp. since December 21, 2010. He was Secretary and Director of Aspreva International Ltd. since September 2004. He served as Secretary of the Board at Copper Fox Metals Inc. He has extensive experience in the corporate, commercial, technology and biotechnology fields since 1978. He served as a Secretary of Med BioGene Inc. from June 2005 to September 2014. He served as Secretary of TIR Systems Ltd. He served as the Chief Executive Officer and President of Sandoz Canada (now Novartis, Canada). He served as Corporate Secretary of Aspreva International Ltd. (formerly known as Aspreva Pharmaceuticals Corporation) since September 2004 and B.C. Leading Edge Endowment Fund. He served as Secretary of Zone Entertainment Group Inc. from June 1999 to November 2000, Gallery Resources Limited from April 1991 to August 2002, American Bullion Minerals Ltd. from May 1997 to June 2001 and Metro Vancouver Properties Corp. (formerly Migenix Inc., Micrologix Inc.) since September 23, 1997. He served as President of CroMedica Global Inc. He has been a Director of Copper Fox Metals Inc. since July 14, 2005. He served as the President of both the United Way of the Lower Mainland and the Vancouver Red Cross. He served as Corporate Secretary for a number of public and private corporations. He represents both senior public companies on complex transactions and early stage private companies providing general and strategic advice on public and private domestic and cross border financings, mergers and acquisitions, corporate reorganizations, international Partnering and licensing transactions. His client list includes many leading technology and life sciences companies in Canada. He served as Chairman of the British Columbia Innovation Council. He served as a Director of Digital Shelf Space Corp. from December 21, 2010 to November 28, 2014, enGene Holdings Inc. (formerly known as enGene, Inc.) since November 2004 and BC Biotech since October 2004. He served as a Director at XBiotech USA, Inc., MedGenesis Therapeutix Inc., British Columbia Leading Edge Endowment Fund and the Innovation and Science Council of British Columbia. He served as a Director of Med BioGene Inc. from 2007 to November 2, 2010 and Aspreva International Ltd. since December 2004. He served as a Director of CANTEST Ltd. and Genome British Columbia, B.C. He is also a Member of the Business in Vancouver Editorial Advisory Board and the Simon Fraser University Biotech Advisory Council. He is recognized by LEXPERT and as being among the Top 100 Canada/U.S. Cross-Border Corporate Lawyers in Canada, named among The Leading 500 Lawyers in Canada and by Best Lawyers as Lawyer of the Year 2020 in biotech in Canada and among Canada's leading lawyers in mergers & acquisitions, technology, corporate and securities and American Lawyer Media in 2004 as one of the 12 named Leading Lawyers in Canada in the field of Technology, which includes Biotechnology and the sole named British Columbia practitioner in that field based on its 2002 survey results of leading practitioners. Frequent lecturer, most recently on "Financial and Non-Financial Disclosure" at the Canadian Investor Relations Institute National Conference Seminar, "The Fundamentals of Investor Relations", January 2002; "Negotiation of a Down Round Financing" at the BC CLE Conference "Corporate Finance and Business Issues for Technology Companies", October 2002; and "Going Public Successfully" at the Insight Financing "High-Tech Companies Conference", November, 2000. He has served as Board Member or officer with Arbutus Biopharma Corp., XBiotech Inc. and QLT Inc., the BC (British Columbia) Tech Association, LifeSciences British Columbia and Tennis Canada. He received the Queen's Counsel designation in 2003 upon recommendation by the Attorney General of British Columbia for exceptional merit and contribution to the legal profession, the "AV Preeminent Legal Ability" rating from Martindale-Hubbell. He holds a B.A. in Economics and an LL.B. from the University of British Columbia. He holds a B.A. (Econ.) from Cambridge University and is a graduate of both the Harvard Advanced Management Program and the Canadian ICD Corporate Governance College.

Positions